> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Advisory Panel to Review Pacira sNDA for Exparel
- URL: https://www.fdaweb.com/fda-advisory-panel-to-review-pacira-snda-for-exparel/
- Published: 2018-01-11T12:00:00.000Z
- Updated: 2026-09-14T23:13:02.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5140473

*Federal Register* notice: FDA has announced a 2/14-15 Anesthetic and Analgesic Drug Products Advisory Committee meeting. Panel members are scheduled to review a Pacira Pharmaceuticals supplemental NDA for Exparel (bupivacaine liposomal injectable suspension), indicated to produce local analgesia and as a nerve block to produce regional analgesia. To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2018-01-11/pdf/2018-00359.pdf?ref=fdaweb.com).